LILLY Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and when can generic versions of LILLY drugs launch?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-seven supplementary protection certificates in thirteen countries.
Summary for LILLY
| International Patents: | 30 |
| US Patents: | 1 |
| Tradenames: | 85 |
| Ingredients: | 81 |
| NDAs: | 105 |
Drugs and US Patents for LILLY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | STREPTOMYCIN SULFATE | streptomycin sulfate | INJECTABLE;INJECTION | 060107-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Lilly | DIETHYLSTILBESTROL | diethylstilbestrol | TABLET, DELAYED RELEASE;ORAL | 004039-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Lilly | CECLOR | cefaclor | FOR SUSPENSION;ORAL | 050522-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Lilly | KEFLIN IN PLASTIC CONTAINER | cephalothin sodium | INJECTABLE;INJECTION | 062549-001 | Sep 10, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Lilly | HEPARIN SODIUM | heparin sodium | INJECTABLE;INJECTION | 005521-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Lilly | MANDOL | cefamandole nafate | INJECTABLE;INJECTION | 050504-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Lilly | NEOMYCIN SULFATE | neomycin sulfate | TABLET;ORAL | 060385-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LILLY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-001 | Nov 21, 2003 | 5,859,006*PED | ⤷ Sign Up |
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 6,894,064 | ⤷ Sign Up |
| Lilly | PROZAC WEEKLY | fluoxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 021235-001 | Feb 26, 2001 | 5,910,319*PED | ⤷ Sign Up |
| Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-001 | Feb 4, 2004 | 5,217,974*PED | ⤷ Sign Up |
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-004 | Jan 7, 2008 | 5,859,006*PED | ⤷ Sign Up |
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,641,790 | ⤷ Sign Up |
| Lilly | SYMBYAX | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 021520-001 | Apr 9, 2007 | 6,960,577 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
| ➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
| ➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
| ➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
| ➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
| ➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
| ➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
| ➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
| ➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
| ➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
| ➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
International Patents for LILLY Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 1732628 | ⤷ Sign Up |
| Japan | 2007530240 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2005097233 | ⤷ Sign Up |
| Eurasian Patent Organization | 009497 | ⤷ Sign Up |
| Eurasian Patent Organization | 200601801 | ⤷ Sign Up |
| Canada | 2557897 | ⤷ Sign Up |
| Poland | 1732629 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for LILLY Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | 2013/055 | Ireland | ⤷ Sign Up | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| 1280520 | C01280520/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 60565 01.02.2012 |
| 1480644 | 2016/056 | Ireland | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF CEFTAZIDIME OR A SALT THEREOF, AND AVIBACTAM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624 |
| 3141251 | 301099 | Netherlands | ⤷ Sign Up | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
| 1480644 | 16C1019 | France | ⤷ Sign Up | PRODUCT NAME: ASSOCIATION OU MELANGE PHARMACEUTIQUE RENFERMANT EN TANT QU'INGREDIENTS ACTIFS:(1) LA CEFTAZIDIME OU UN DES SES SELS ET (2) L'AVIBACTAM OU UN DE SES SELS; REGISTRATION NO/DATE: EU/1/16/1109 20160628 |
| 0705275 | SPC/GB00/027 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801 |
| 2957286 | 300962 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
